Digitisation | November 14, 2023
BioPhy launches AI platform to accelerate the drug development market
The company has raised US$4.5 million in funding for its AI operating system
The company has raised US$4.5 million in funding for its AI operating system
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Augnito’s AI comprehends all English accents with 99% accuracy
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Subscribe To Our Newsletter & Stay Updated
